Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose — 32 U.S. Jurisdictions, July 31–September 3, 2022
Amanda B. Payne, Logan C. Ray, Kiersten J. Kugeler, Amy Fothergill, Elizabeth B. White, Michelle Canning, Jennifer L. Farrar, Leora R. Feldstein, Adi V. Gundlapalli, Kennedy Houck, Jennifer L. Kriss, Nathaniel M. Lewis, Emily Sims, Dawn K. Smith, Ian H. Spicknall, Yoshinori Nakazawa, Inger K. Damon, Amanda Cohn, Daniel C. Payne
Abstract
aged 18-49 years during July 31-September 3, 2022, were analyzed by vaccination status across 32 U.S. jurisdictions.** Average monkeypox incidence (cases per 100,000) among unvaccinated persons was 14.3 (95% CI = 5.0-41.0) times that among persons who received 1 dose of JYNNEOS vaccine ≥14 days earlier. Monitoring monkeypox incidence by vaccination status in timely surveillance data might provide early indications of vaccine-related protection that can be confirmed through other well-controlled vaccine effectiveness studies. This early finding suggests that a single dose of JYNNEOS vaccine provides some protection against monkeypox infection. The degree and durability of such protection is unknown, and it is recommended that people who are eligible for monkeypox vaccination receive the complete 2-dose series.